Imatinib

Kidney Cancer

University of Medicine and Dentistry of New JerseySmall moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

70 Active assets in the Kidney Cancer cohort.

Asset / Sponsor	Phase	Rating
Alpha-Interferon Dartmouth-Hitchcock Medical Center	Phase 3	BBB
Girentuximab Memorial Sloan Kettering Cancer Center	Phase 3	BB
Girentuximab Heidelberg Pharma AG	Phase 3	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
FLUOROURACILUM Medical Research Council	Phase 3	BB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.